🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

MannKind Corporation MNKD R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://mannkindcorp.com
Company Profile ↓
$4.06
+8.85% 1Y
Mkt Cap$1.31B
P/E-27.07
P/B-24.76
52W High$6.21
52W Low$2.28
Book Value$-0.17
EPS (TTM)$-0.15

Company Overview

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 73.1% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $348.97M (+22.2% YoY); net profit $5.86M.
  • Trailing 12 Months Year-on-year growth — revenue +42.9%, earnings -78.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 73.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:73.10%
1 Year:42.90%

Compounded Profit Growth

5 Years:-
1 Year:-78.75%

Stock Price Performance

1 Year:+8.85%
6 Months:+55.56%
3 Months:+19.41%
1 Month:+4.37%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 45% of range
$2.28 $6.21
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)51.61 · Neutral
Price Performance
1M+4.37%
3M+19.41%
6M+55.56%
1Y+8.85%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 73.1% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 34.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-27.07
Industry PE
25.17
Forward P/E
25.37
PEG Ratio
4.39
Book Value
$-0.17
Price to Book
-24.76
P/S
3.36
EV/EBITDA
58.41
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
73.10%
Profit 5Y
-
Revenue (YoY)
42.90%
Earnings (YoY)
-78.75%

Profitability & Returns

ROCE
6.25%
ROE
-11.49%
ROA
0.79%
Profit Margin
-11.08%
Op Margin
-0.76%
Gross Margin
75.39%
EPS (Latest Qtr)
$-0.06
EPS (TTM)
$-0.15

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
1.08
Current Ratio
1.72
Debt
$432.96M
Total Assets
$732.30M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.47%
Chg in Prom Hold
-0.01%
FII / Inst Holding
57.29%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
$1.31B
Total Revenue (TTM)
$393.63M
EBITDA
$28.14M
Free Cash Flow
$37.40M
Operating Cash Flow
$-8.05M
Shares Outstanding
321.54M
Gross Margin
75.39%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MNKD MannKind Corporation R2KR3KPHARMA 4.06 -27.07 $1.31B 0.00% 6.25% -11.49% 73.10% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue --------3.01M2.16M2.04M4.53M3.46M3.89M4.47M16.03M17.45M15.00M14.60M15.99M16.23M15.11M15.35M17.44M23.28M22.21M11.99M18.89M32.83M40.63M48.61M51.25M66.26M72.39M70.08M78.35M76.53M82.13M90.17M109.37M
Operating Income -21.74M-24.05M-26.00M--20.01M-19.12M118.23M--19.60M-31.57M-28.18M--26.79M-20.54M-21.54M--13.51M-10.95M-8.78M--7.12M-7.92M-9.13M-6.19M-10.27M-6.59M-21.26M-20.45M-9.61M-6.00M1.72M5.10M16.72M16.61M12.76M22.29M5.30M18.90M-1.67M-350.00K
Net Income -30.66M-28.91M-31.86M-277.02M-24.87M-29.96M126.52M53.98M-16.32M-35.34M-32.89M-32.78M-30.39M-22.68M-24.17M-9.75M-14.88M-12.39M-10.37M-14.26M-9.32M-10.25M-11.26M-12.92M-35.52M-4.43M-26.00M-29.02M-14.43M-9.79M-5.26M1.72M10.63M-2.01M11.55M13.16M668.00K7.99M-16.62M-19.03M
Diluted EPS ---0.08--0.29-0.331.310.56-0.17-0.35-0.31-0.28-0.25-0.16-0.16-0.06---------0.14-0.02-0.10-0.11-0.06-0.04-0.020.010.04-0.010.040.040.000.03-0.05-0.06

Profit & Loss (Annual)

Figures in USD.

Metric Feb 1992Feb 1993Feb 1994Dec 1994Dec 1995Dec 1996Dec 1997Dec 1998Dec 1999Dec 2000Dec 2001Dec 2002Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------------------93.00K50.00K35.00K000174.76M11.74M27.86M63.04M65.14M75.44M99.77M198.96M285.50M348.97M
Operating Income -------------------209.78M-152.50M-140.54M-146.96M-169.40M-179.63M-344.65M67.26M-108.19M-76.59M-44.60M-47.91M-47.02M-64.11M8.68M72.59M38.80M
Net Income -911.00K-1.18M-1.16M-2.00M-2.81M-2.57M-2.28M-3.33M-5.68M-24.66M-48.24M-206.26M-65.88M-75.99M-114.34M-230.55M-293.19M-303.04M-220.10M-170.56M-160.80M-169.37M-191.49M-198.38M-368.44M125.66M-117.33M-86.97M-51.90M-57.24M-80.93M-87.40M-11.94M27.59M5.86M
Diluted EPS ------------------------2.57-4.541.36-1.13-0.60--0.26-0.32-0.34-0.040.100.02

Balance Sheet (Annual)

Figures in USD.

Metric Feb 1992Feb 1993Feb 1994Dec 1994Dec 1995Dec 1996Dec 1997Dec 1998Dec 1999Dec 2000Dec 2001Dec 2002Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -------------------277.26M199.55M251.31M258.65M394.44M126.41M107.06M84.58M107.70M93.72M108.61M321.16M295.28M475.20M393.84M792.18M
Total Equity -11.00K-278.00K-908.00K-707.00K-3.11M-5.48M-7.37M3.40M-746.00K31.89M235.02M90.77M111.58M150.36M206.98M383.49M364.10M86.73M-59.22M-185.53M-313.65M-110.68M-30.71M-73.77M-350.33M-183.59M-214.73M-175.08M-190.53M-180.42M-209.35M-250.54M-246.17M-78.82M-51.02M
Cash & Equivalents -----------------27.65M30.02M66.06M2.68M61.84M70.79M120.84M59.07M22.89M43.95M71.16M29.91M67.00M124.18M69.77M238.48M46.34M74.88M
Long Term Debt ---------------------------102.49M118.90M122.23M281.20M273.49M268.70M36.05M354.64M
Total Liabilities -------------------462.79M513.21M361.99M289.36M468.21M476.74M290.66M299.31M282.79M284.25M289.03M530.51M545.82M721.37M472.66M843.20M
Current Liabilities -------------------18.13M25.36M144.78M127.79M403.35M268.32M92.05M87.60M75.24M65.62M73.70M48.35M67.30M104.12M81.84M171.03M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -184.08M-148.65M-123.84M-119.86M-128.73M---78.09M-64.78M-37.73M-88.48M-28.13M-61.71M-80.68M34.09M42.51M18.25M
Investing Cash Flow -3.05M-11.72M-2.94M-560.00K-7.99M---1.13M16.68M-234.00K-22.84M15.22M-151.54M4.87M-1.99M-96.65M-304.80M
Financing Cash Flow 189.51M196.42M63.39M179.58M145.67M--43.04M73.56M61.29M69.86M49.85M270.27M21.39M136.61M-137.27M315.10M
Capital Expenditure -18.85M-9.54M-6.86M-637.00K-7.99M-24.10M-10.29M-1.14M--354.00K-2.56M-801.00K-11.47M-7.59M-42.44M-9.69M-4.57M
Free Cash Flow -202.94M-158.20M-130.69M-120.50M-136.72M---79.23M--38.09M-91.05M-28.93M-73.17M-88.27M-8.35M32.82M13.69M

Ratios (Annual)

Figures in %.

Metric Feb 1992Feb 1993Feb 1994Dec 1994Dec 1995Dec 1996Dec 1997Dec 1998Dec 1999Dec 2000Dec 2001Dec 2002Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------------------------
Operating Margin % --------------------163,976.3%-281,078.0%-419,885.7%---38.5%-921.1%-274.9%-70.7%-73.5%-62.3%-64.3%4.4%25.4%11.1%
Net Margin % --------------------183,397.8%-321,608.0%-483,902.9%---71.9%-999.0%-312.2%-82.3%-87.9%-107.3%-87.6%-6.0%9.7%1.7%
ROE % 8,281.8%422.7%127.3%283.5%90.6%46.9%30.9%-97.9%761.3%-77.3%-20.5%-227.2%-59.0%-50.5%-55.2%-60.1%-80.5%-349.4%371.7%91.9%51.3%153.0%623.5%268.9%105.2%-68.4%54.6%49.7%27.2%31.7%38.7%34.9%4.8%-35.0%-11.5%
ROCE % --------------------58.9%-80.7%-137.9%-129.5%2,015.1%242.9%448.0%3,580.0%-235.9%-158.7%-137.3%-17.2%-28.1%2.3%23.3%6.2%

Shareholding Pattern

Insiders
1.47%
Institutions
57.29%
Public Float
58.15%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.99% 32.13M $126.93M
2 Rubric Capital Management LP 5.60% 18.00M $71.10M
3 State Street Corporation 5.03% 16.17M $63.89M
4 Vanguard Capital Management LLC 4.10% 13.17M $52.02M
5 Geode Capital Management, LLC 2.47% 7.95M $31.39M
6 Wellington Management Group, LLP 2.44% 7.84M $30.99M
7 Frazier Life Sciences Management, L.P. 2.05% 6.60M $26.07M
8 Deep Track Capital, Lp 1.87% 6.00M $23.70M
9 180 Wealth Advisors, LLC 1.54% 4.96M $19.59M
10 FMR, LLC 1.28% 4.10M $16.20M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MNKD

Yahoo Finance Wed, 02 Sep 2026

MannKind to Present at Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences: C…

Yahoo Finance Sat, 29 Aug 2026

MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative

MannKind (MNKD) continues to draw attention after recent share price moves, with the stock closing at US$3.95. Investors are weighing its current market value of about US$1.31b against its latest financial profile. Over the past year, MannK…

Yahoo Finance hu, 06 Aug 2026

MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says

MannKind's (MNKD) increasingly diversified portfolio is seen bringing in higher revenue in H2, with

Yahoo Finance hu, 06 Aug 2026

MannKind Q2 Earnings Call Highlights

MannKind (NASDAQ:MNKD) reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and develo…

Yahoo Finance Wed, 05 Aug 2026

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.…

Yahoo Finance Wed, 05 Aug 2026

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MNKD — Frequently Asked Questions

What is the current share price of MannKind Corporation (MNKD)?

As of 2026-09-07 16:24 PDT, MannKind Corporation (MNKD) trades at $4.06 on NasdaqGM. Its 52-week range is $2.28 to $6.21.

What is the market capitalisation of MNKD?

MannKind Corporation (MNKD) has a market capitalisation of $1.31B on NasdaqGM.

What is the P/E ratio of MNKD?

MNKD trades at a trailing price-to-earnings (P/E) ratio of -27.07. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -24.76.

What is the return on equity (ROE) of MNKD?

MNKD has a return on equity (ROE) of -11.49%. Its return on capital employed (ROCE) is 6.25%.

Is MNKD a good stock to buy?

This page provides a data-driven analysis of MannKind Corporation (MNKD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space